$MEI Pharma (MEIP.US)$ NEWS MEI Pharma Reports Initial Data ...
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the decision to advance ME-344 via a new formulation for increased biological activity and commercial opportunities.
Positive results from Cohort 1 of the Phase 1b study with 25% of patients showing no disease progression at Week 16.
Exceeded the 20% threshold to add more patients to the study, indicating promising efficacy.
ME-344 in combination with bevacizumab was generally well-tolerated with no overlapping toxicities.
Decision to advance ME-344 via a new formulation to increase biological activity and commercial opportunities.
Encouraging results from the research and development of the new formulation.
Focus on improving patient outcomes and treatment convenience while reducing expenditures on the program.
Exceeded the 20% threshold to add more patients to the study, indicating promising efficacy.
ME-344 in combination with bevacizumab was generally well-tolerated with no overlapping toxicities.
Decision to advance ME-344 via a new formulation to increase biological activity and commercial opportunities.
Encouraging results from the research and development of the new formulation.
Focus on improving patient outcomes and treatment convenience while reducing expenditures on the program.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
401Followers
64Following
2606Visitors
Follow